메뉴 건너뛰기




Volumn 15, Issue 1, 2013, Pages 15-27

GLP-1 receptor activated insulin secretion from pancreatic β-cells: Mechanism and glucose dependence

Author keywords

Antidiabetic drug; Drug mechanism; GLP 1; Insulin secretion; Type 2 diabetes; cell

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; CALCIUM CHANNEL; CYCLIC AMP; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA;

EID: 84871166499     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01663.x     Document Type: Review
Times cited : (264)

References (97)
  • 1
    • 64649104158 scopus 로고    scopus 로고
    • Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
    • DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
    • (2009) Diabetes , vol.58 , pp. 773-795
    • DeFronzo, R.A.1
  • 2
    • 84864285795 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1577-1596.
    • (2012) Diabetes Care , vol.35 , pp. 1577-1596
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 5
    • 0031793981 scopus 로고    scopus 로고
    • Hypoglycaemia leads to an increased QT interval in normal men
    • Eckert B, Agardh CD. Hypoglycaemia leads to an increased QT interval in normal men. Clin Physiol 1998; 18: 570-575.
    • (1998) Clin Physiol , vol.18 , pp. 570-575
    • Eckert, B.1    Agardh, C.D.2
  • 6
    • 0032424866 scopus 로고    scopus 로고
    • Electrocardiographic changes during insulin-induced hypoglycemia in healthy subjects
    • Meinhold J, Heise T, Rave K, Heinemann L. Electrocardiographic changes during insulin-induced hypoglycemia in healthy subjects. Horm Metab Res 1998; 30: 694-697.
    • (1998) Horm Metab Res , vol.30 , pp. 694-697
    • Meinhold, J.1    Heise, T.2    Rave, K.3    Heinemann, L.4
  • 7
    • 79956095353 scopus 로고    scopus 로고
    • Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes
    • Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011; 34: 1164-1170.
    • (2011) Diabetes Care , vol.34 , pp. 1164-1170
    • Johnston, S.S.1    Conner, C.2    Aagren, M.3    Smith, D.M.4    Bouchard, J.5    Brett, J.6
  • 8
    • 79251567403 scopus 로고    scopus 로고
    • Serious cardiovascular outcomes in diabetes: the role of hypoglycemia
    • Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 2011; 123: 342-348.
    • (2011) Circulation , vol.123 , pp. 342-348
    • Yakubovich, N.1    Gerstein, H.C.2
  • 9
    • 80054967262 scopus 로고    scopus 로고
    • Death during intensive glycemic therapy of diabetes: mechanisms and implications
    • Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med 2011; 124: 993-996.
    • (2011) Am J Med , vol.124 , pp. 993-996
    • Cryer, P.E.1
  • 10
    • 82455210942 scopus 로고    scopus 로고
    • Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells
    • Leech CA, Dzhura I, Chepurny OG et al. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells. Prog Biophys Mol Biol 2011; 104: 236-247.
    • (2011) Prog Biophys Mol Biol , vol.104 , pp. 236-247
    • Leech, C.A.1    Dzhura, I.2    Chepurny, O.G.3
  • 11
    • 0036307610 scopus 로고    scopus 로고
    • The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects
    • Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 2002; 146: 863-869.
    • (2002) Eur J Endocrinol , vol.146 , pp. 863-869
    • Hui, H.1    Farilla, L.2    Merkel, P.3    Perfetti, R.4
  • 12
    • 34248223285 scopus 로고    scopus 로고
    • Biology of incretins: GLP-1 and GIP
    • Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
    • (2007) Gastroenterology , vol.132 , pp. 2131-2157
    • Baggio, L.L.1    Drucker, D.J.2
  • 13
    • 58149090676 scopus 로고    scopus 로고
    • The role of incretins in glucose homeostasis and diabetes treatment
    • Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470-512.
    • (2008) Pharmacol Rev , vol.60 , pp. 470-512
    • Kim, W.1    Egan, J.M.2
  • 14
    • 79959778328 scopus 로고    scopus 로고
    • Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability
    • Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011; 34(Suppl 2): S279-S284.
    • (2011) Diabetes Care , vol.34 , Issue.SUPPL 2
    • Garber, A.J.1
  • 15
    • 77950827693 scopus 로고    scopus 로고
    • Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes
    • Apovian CM, Bergenstal RM, Cuddihy RM et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010; 123: 468.e9-468.e17.
    • (2010) Am J Med , vol.123
    • Apovian, C.M.1    Bergenstal, R.M.2    Cuddihy, R.M.3
  • 16
    • 77955573674 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    • Bergenstal RM, Wysham C, MacConell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439.
    • (2010) Lancet , vol.376 , pp. 431-439
    • Bergenstal, R.M.1    Wysham, C.2    MacConell, L.3
  • 17
    • 79955661908 scopus 로고    scopus 로고
    • DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    • Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310.
    • (2011) J Clin Endocrinol Metab , vol.96 , pp. 1301-1310
    • Blevins, T.1    Pullman, J.2    Malloy, J.3
  • 18
    • 77953859640 scopus 로고    scopus 로고
    • Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
    • Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
    • (2010) Lancet , vol.375 , pp. 2234-2243
    • Diamant, M.1    Van Gaal, L.2    Stranks, S.3
  • 19
    • 53249142132 scopus 로고    scopus 로고
    • Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
    • Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
    • (2008) Lancet , vol.372 , pp. 1240-1250
    • Drucker, D.J.1    Buse, J.B.2    Taylor, K.3
  • 20
    • 79951906623 scopus 로고    scopus 로고
    • Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2years as monotherapy compared with glimepiride in patients with type 2 diabetes
    • Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 348-356.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 348-356
    • Garber, A.1    Henry, R.R.2    Ratner, R.3    Hale, P.4    Chang, C.T.5    Bode, B.6
  • 21
    • 77958540163 scopus 로고    scopus 로고
    • A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin
    • Liutkus J, Rosas Guzman J, Norwood P et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab 2010; 12: 1058-1065.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 1058-1065
    • Liutkus, J.1    Rosas Guzman, J.2    Norwood, P.3
  • 22
    • 62449169287 scopus 로고    scopus 로고
    • Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study
    • Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
    • (2009) Diabetes Care , vol.32 , pp. 84-90
    • Nauck, M.1    Frid, A.2    Hermansen, K.3
  • 23
    • 69949117621 scopus 로고    scopus 로고
    • Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
    • Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
    • (2009) Diabetologia , vol.52 , pp. 2046-2055
    • Russell-Jones, D.1    Vaag, A.2    Schmitz, O.3
  • 25
    • 0018888159 scopus 로고
    • Insulinotropic factors of the gut-the broadening incretin concept
    • Creutzfeldt W. Insulinotropic factors of the gut-the broadening incretin concept. Gastroenterology 1980; 78: 1631-1632.
    • (1980) Gastroenterology , vol.78 , pp. 1631-1632
    • Creutzfeldt, W.1
  • 26
    • 0021864130 scopus 로고
    • New developments in the incretin concept
    • Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985; 28: 565-573.
    • (1985) Diabetologia , vol.28 , pp. 565-573
    • Creutzfeldt, W.1    Ebert, R.2
  • 27
    • 0026080393 scopus 로고
    • GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse
    • Fridolf T, Böttcher G, Sundler F, Ahrén B. GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 1991; 6: 208-215.
    • (1991) Pancreas , vol.6 , pp. 208-215
    • Fridolf, T.1    Böttcher, G.2    Sundler, F.3    Ahrén, B.4
  • 28
    • 0027523613 scopus 로고
    • Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas
    • Göke R, Wagner B, Fehmann HC, Göke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berl) 1993; 193: 97-103.
    • (1993) Res Exp Med (Berl) , vol.193 , pp. 97-103
    • Göke, R.1    Wagner, B.2    Fehmann, H.C.3    Göke, B.4
  • 29
    • 0031724691 scopus 로고    scopus 로고
    • Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure
    • Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998; 21: 1925-1931.
    • (1998) Diabetes Care , vol.21 , pp. 1925-1931
    • Nauck, M.A.1    Sauerwald, A.2    Ritzel, R.3    Holst, J.J.4    Schmiegel, W.5
  • 30
    • 0028904931 scopus 로고
    • Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects
    • Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995; 32: 13-16.
    • (1995) Acta Diabetol , vol.32 , pp. 13-16
    • Qualmann, C.1    Nauck, M.A.2    Holst, J.J.3    Orskov, C.4    Creutzfeldt, W.5
  • 31
    • 4344713643 scopus 로고    scopus 로고
    • Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia
    • Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397-2403.
    • (2004) Diabetes , vol.53 , pp. 2397-2403
    • Degn, K.B.1    Brock, B.2    Juhl, C.B.3
  • 32
    • 0034602252 scopus 로고    scopus 로고
    • Sustained expression of exendin-4 does not perturb glucose homeostasis, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice
    • Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ. Sustained expression of exendin-4 does not perturb glucose homeostasis, β-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 2000; 275: 34471-34477.
    • (2000) J Biol Chem , vol.275 , pp. 34471-34477
    • Baggio, L.1    Adatia, F.2    Bock, T.3    Brubaker, P.L.4    Drucker, D.J.5
  • 33
    • 0028058718 scopus 로고
    • Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action
    • Montrose-Rafizadeh C, Egan JM, Roth J. Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action. Endocrinology 1994; 135: 589-594.
    • (1994) Endocrinology , vol.135 , pp. 589-594
    • Montrose-Rafizadeh, C.1    Egan, J.M.2    Roth, J.3
  • 34
    • 0036965113 scopus 로고    scopus 로고
    • The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes
    • Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-1290.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 1282-1290
    • Egan, J.M.1    Clocquet, A.R.2    Elahi, D.3
  • 35
    • 56549107405 scopus 로고    scopus 로고
    • Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
    • Linnebjerg H, Park S, Kothare PA et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-129.
    • (2008) Regul Pept , vol.151 , pp. 123-129
    • Linnebjerg, H.1    Park, S.2    Kothare, P.A.3
  • 36
    • 84859013614 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study
    • Russell-Jones D, Cuddihy RM, Hanefeld M et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012; 35: 252-258.
    • (2012) Diabetes Care , vol.35 , pp. 252-258
    • Russell-Jones, D.1    Cuddihy, R.M.2    Hanefeld, M.3
  • 37
    • 34249869806 scopus 로고    scopus 로고
    • Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
    • Vilsbøll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
    • (2007) Diabetes Care , vol.30 , pp. 1608-1610
    • Vilsbøll, T.1    Zdravkovic, M.2    Le-Thi, T.3
  • 38
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes
    • DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
    • (2005) Diabetes Care , vol.28 , pp. 1092-1100
    • DeFronzo, R.A.1    Ratner, R.E.2    Han, J.3    Kim, D.D.4    Fineman, M.S.5    Baron, A.D.6
  • 39
    • 51549095571 scopus 로고    scopus 로고
    • Efficacy and tolerability of exenatide monotherapy over 24weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study
    • Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008; 30: 1448-1460.
    • (2008) Clin Ther , vol.30 , pp. 1448-1460
    • Moretto, T.J.1    Milton, D.R.2    Ridge, T.D.3
  • 40
    • 34247259577 scopus 로고    scopus 로고
    • The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial
    • Zinman B, Hoogwerf BJ, Durán García S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.
    • (2007) Ann Intern Med , vol.146 , pp. 477-485
    • Zinman, B.1    Hoogwerf, B.J.2    Durán García, S.3
  • 41
    • 79551615182 scopus 로고    scopus 로고
    • Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
    • Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103-112.
    • (2011) Ann Intern Med , vol.154 , pp. 103-112
    • Buse, J.B.1    Bergenstal, R.M.2    Glass, L.C.3
  • 42
    • 84862302997 scopus 로고    scopus 로고
    • Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised trial
    • Gallwitz B, Guzman J, Dotta F et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised trial. Lancet 2012; 379: 2270-2278.
    • (2012) Lancet , vol.379 , pp. 2270-2278
    • Gallwitz, B.1    Guzman, J.2    Dotta, F.3
  • 43
    • 84859879074 scopus 로고    scopus 로고
    • Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of exenatide twice-daily
    • Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of exenatide twice-daily. Endocr Pract 2012; 18: 227-237.
    • (2012) Endocr Pract , vol.18 , pp. 227-237
    • Pencek, R.1    Brunell, S.C.2    Li, Y.3    Hoogwerf, B.J.4    Malone, J.5
  • 44
    • 84857385645 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomized, open-label study
    • Buse JB, Nauck M, Forst T et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomized, open-label study. Diabetologia 2011; 54: S38.
    • (2011) Diabetologia , vol.54
    • Buse, J.B.1    Nauck, M.2    Forst, T.3
  • 45
    • 77953103244 scopus 로고    scopus 로고
    • Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes
    • Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH, Aronoff S. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med 2010; 122: 118-128.
    • (2010) Postgrad Med , vol.122 , pp. 118-128
    • Blevins, T.1    Han, J.2    Nicewarner, D.3    Chen, S.4    Oliveira, J.H.5    Aronoff, S.6
  • 46
    • 66149151676 scopus 로고    scopus 로고
    • GLUT2 mutations, translocation, and receptor function in diet sugar managing
    • Leturque A, Brot-Laroche E, Le Gall M. GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am J Physiol Endocrinol Metab 2009; 296: E985-E992.
    • (2009) Am J Physiol Endocrinol Metab , vol.296
    • Leturque, A.1    Brot-Laroche, E.2    Le Gall, M.3
  • 47
    • 0028859374 scopus 로고
    • Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression
    • De Vos A, Heimberg H, Quartier E et al. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest 1995; 96: 2489-2495.
    • (1995) J Clin Invest , vol.96 , pp. 2489-2495
    • De Vos, A.1    Heimberg, H.2    Quartier, E.3
  • 48
    • 33847617011 scopus 로고    scopus 로고
    • Mechanisms of action of glucagon-like peptide 1 in the pancreas
    • Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113: 546-593.
    • (2007) Pharmacol Ther , vol.113 , pp. 546-593
    • Doyle, M.E.1    Egan, J.M.2
  • 49
    • 10644293820 scopus 로고    scopus 로고
    • Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential
    • Gromada J, Brock B, Schmitz O, Rorsman P. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 2004; 95: 252-262.
    • (2004) Basic Clin Pharmacol Toxicol , vol.95 , pp. 252-262
    • Gromada, J.1    Brock, B.2    Schmitz, O.3    Rorsman, P.4
  • 50
    • 0032500529 scopus 로고    scopus 로고
    • Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA
    • Gribble FM, Proks P, Corkey BE, Ashcroft FM. Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA. J Biol Chem 1998; 273: 26383-26387.
    • (1998) J Biol Chem , vol.273 , pp. 26383-26387
    • Gribble, F.M.1    Proks, P.2    Corkey, B.E.3    Ashcroft, F.M.4
  • 51
    • 0033623178 scopus 로고    scopus 로고
    • KATP channels gated by intracellular nucleotides and phospholipids
    • Baukrowitz T, Fakler B. KATP channels gated by intracellular nucleotides and phospholipids. Eur J Biochem 2000; 267: 5842-5848.
    • (2000) Eur J Biochem , vol.267 , pp. 5842-5848
    • Baukrowitz, T.1    Fakler, B.2
  • 52
    • 0033556082 scopus 로고    scopus 로고
    • Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion
    • Lang J. Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion. Eur J Biochem 1999; 259: 3-17.
    • (1999) Eur J Biochem , vol.259 , pp. 3-17
    • Lang, J.1
  • 53
    • 0042879951 scopus 로고    scopus 로고
    • Insulin granule dynamics in pancreatic β cells
    • Rorsman P, Renström E. Insulin granule dynamics in pancreatic β cells. Diabetologia 2003; 46: 1029-1045.
    • (2003) Diabetologia , vol.46 , pp. 1029-1045
    • Rorsman, P.1    Renström, E.2
  • 56
    • 0036310678 scopus 로고    scopus 로고
    • 2+ channels accounts for first-phase insulin secretion in mouse β cells
    • 2+ channels accounts for first-phase insulin secretion in mouse β cells. Diabetes 2002; 51(Suppl 1): S74-S82.
    • (2002) Diabetes , vol.51 , Issue.SUPPL 1
    • Barg, S.1    Eliasson, L.2    Renström, E.3    Rorsman, P.4
  • 57
    • 9444238518 scopus 로고    scopus 로고
    • Stimulation of insulin release by glucose is associated with an increase in the number of docked granules in the β cells of rat pancreatic islets
    • Straub SG, Shanmugam G, Sharp GW. Stimulation of insulin release by glucose is associated with an increase in the number of docked granules in the β cells of rat pancreatic islets. Diabetes 2004; 53: 3179-3183.
    • (2004) Diabetes , vol.53 , pp. 3179-3183
    • Straub, S.G.1    Shanmugam, G.2    Sharp, G.W.3
  • 58
    • 66849115296 scopus 로고    scopus 로고
    • Mechanisms of biphasic insulin-granule exocytosis-roles of the cytoskeleton, small GTPases and SNARE proteins
    • Wang Z, Thurmond DC. Mechanisms of biphasic insulin-granule exocytosis-roles of the cytoskeleton, small GTPases and SNARE proteins. J Cell Sci 2009; 122: 893-903.
    • (2009) J Cell Sci , vol.122 , pp. 893-903
    • Wang, Z.1    Thurmond, D.C.2
  • 60
    • 0036310679 scopus 로고    scopus 로고
    • Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion
    • Bratanova-Tochkova TK, Cheng H, Daniel S et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 2002; 51(Suppl 1): S83-S90.
    • (2002) Diabetes , vol.51 , Issue.SUPPL 1
    • Bratanova-Tochkova, T.K.1    Cheng, H.2    Daniel, S.3
  • 61
    • 0036720536 scopus 로고    scopus 로고
    • Ion channels in secretory granules of the pancreas and their role in exocytosis and release of secretory proteins
    • Thevenod F. Ion channels in secretory granules of the pancreas and their role in exocytosis and release of secretory proteins. Am J Physiol Cell Physiol 2002; 283: C651-C672.
    • (2002) Am J Physiol Cell Physiol , vol.283
    • Thevenod, F.1
  • 62
    • 70349632869 scopus 로고    scopus 로고
    • Suppression of sulfonylurea- and glucose-induced insulin secretion in vitro and in vivo in mice lacking the chloride transport protein ClC-3
    • Li DQ, Jing X, Salehi A et al. Suppression of sulfonylurea- and glucose-induced insulin secretion in vitro and in vivo in mice lacking the chloride transport protein ClC-3. Cell Metab 2009; 10: 309-315.
    • (2009) Cell Metab , vol.10 , pp. 309-315
    • Li, D.Q.1    Jing, X.2    Salehi, A.3
  • 63
    • 0028358092 scopus 로고
    • The insulin gene contains multiple transcriptional elements that respond to glucose
    • German MS, Wang J. The insulin gene contains multiple transcriptional elements that respond to glucose. Mol Cell Biol 1994; 14: 4067-4075.
    • (1994) Mol Cell Biol , vol.14 , pp. 4067-4075
    • German, M.S.1    Wang, J.2
  • 64
    • 0142149134 scopus 로고    scopus 로고
    • Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet β cells but not regulated via a positive feedback of secreted insulin
    • Wicksteed B, Alarcon C, Briaud I, Lingohr MK, Rhodes CJ. Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet β cells but not regulated via a positive feedback of secreted insulin. J Biol Chem 2003; 278: 42080-42090.
    • (2003) J Biol Chem , vol.278 , pp. 42080-42090
    • Wicksteed, B.1    Alarcon, C.2    Briaud, I.3    Lingohr, M.K.4    Rhodes, C.J.5
  • 66
    • 45549098329 scopus 로고    scopus 로고
    • Glucose-induced cyclic AMP oscillations regulate pulsatile insulin secretion
    • Dyachok O, Idevall-Hagren O, Sågetorp J et al. Glucose-induced cyclic AMP oscillations regulate pulsatile insulin secretion. Cell Metab 2008; 8: 26-37.
    • (2008) Cell Metab , vol.8 , pp. 26-37
    • Dyachok, O.1    Idevall-Hagren, O.2    Sågetorp, J.3
  • 67
    • 0036718447 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism
    • Light PE, Manning Fox JE, Riedel MJ, Wheeler MB. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol Endocrinol 2002; 16: 2135-2144.
    • (2002) Mol Endocrinol , vol.16 , pp. 2135-2144
    • Light, P.E.1    Manning Fox, J.E.2    Riedel, M.J.3    Wheeler, M.B.4
  • 68
    • 50449094096 scopus 로고    scopus 로고
    • Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells
    • Ramos LS, Zippin JH, Kamenetsky M, Buck J, Levin LR. Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells. J Gen Physiol 2008; 132: 329-338.
    • (2008) J Gen Physiol , vol.132 , pp. 329-338
    • Ramos, L.S.1    Zippin, J.H.2    Kamenetsky, M.3    Buck, J.4    Levin, L.R.5
  • 69
    • 67449092561 scopus 로고    scopus 로고
    • Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2'-O-Me-cAMP-AM
    • Chepurny OG, Leech CA, Kelley GG et al. Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2'-O-Me-cAMP-AM. J Biol Chem 2009; 284: 10728-10736.
    • (2009) J Biol Chem , vol.284 , pp. 10728-10736
    • Chepurny, O.G.1    Leech, C.A.2    Kelley, G.G.3
  • 70
    • 31544449107 scopus 로고    scopus 로고
    • Cyclic AMP/cAMP-GEF pathway amplifies insulin exocytosis induced by Ca2+ and ATP in rat islet β-cells
    • Hashiguchi H, Nakazaki M, Koriyama N, Fukudome M, Aso K, Tei C. Cyclic AMP/cAMP-GEF pathway amplifies insulin exocytosis induced by Ca2+ and ATP in rat islet β-cells. Diabetes Metab Res Rev 2006; 22: 64-71.
    • (2006) Diabetes Metab Res Rev , vol.22 , pp. 64-71
    • Hashiguchi, H.1    Nakazaki, M.2    Koriyama, N.3    Fukudome, M.4    Aso, K.5    Tei, C.6
  • 71
    • 77349114753 scopus 로고    scopus 로고
    • Glucose-dependent potentiation of mouse islet insulin secretion by Epac activator 8-pCPT-2'-O-Me-cAMP-AM
    • Kelley GG, Chepurny OG, Schwede F et al. Glucose-dependent potentiation of mouse islet insulin secretion by Epac activator 8-pCPT-2'-O-Me-cAMP-AM. Islets 2009; 1: 260-265.
    • (2009) Islets , vol.1 , pp. 260-265
    • Kelley, G.G.1    Chepurny, O.G.2    Schwede, F.3
  • 73
    • 0033769693 scopus 로고    scopus 로고
    • cAMP-GEFII is a direct target of cAMP in regulated exocytosis
    • Ozaki N, Shibasaki T, Kashima Y et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000; 2: 805-811.
    • (2000) Nat Cell Biol , vol.2 , pp. 805-811
    • Ozaki, N.1    Shibasaki, T.2    Kashima, Y.3
  • 76
    • 0042879894 scopus 로고    scopus 로고
    • + channels in pancreatic β cells: role, regulation and potential as therapeutic targets
    • + channels in pancreatic β cells: role, regulation and potential as therapeutic targets. Diabetologia 2003; 46: 1046-1062.
    • (2003) Diabetologia , vol.46 , pp. 1046-1062
    • MacDonald, P.E.1    Wheeler, M.B.2
  • 78
    • 0036896712 scopus 로고    scopus 로고
    • + currents in β cells: a possible glucose-dependent insulinotropic mechanism
    • + currents in β cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 2002; 51(Suppl 3): S443-S447.
    • (2002) Diabetes , vol.51 , Issue.SUPPL 3
    • MacDonald, P.E.1    Salapatek, A.M.2    Wheeler, M.B.3
  • 79
    • 0031965604 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic β cells by both proximal and distal regulatory steps in stimulus-secretion coupling
    • Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic β cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 1998; 47: 57-65.
    • (1998) Diabetes , vol.47 , pp. 57-65
    • Gromada, J.1    Bokvist, K.2    Ding, W.G.3    Holst, J.J.4    Nielsen, J.H.5    Rorsman, P.6
  • 80
    • 0033304574 scopus 로고    scopus 로고
    • Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells
    • Salapatek AM, MacDonald PE, Gaisano HY, Wheeler MB. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells. Mol Endocrinol 1999; 13: 1305-1317.
    • (1999) Mol Endocrinol , vol.13 , pp. 1305-1317
    • Salapatek, A.M.1    MacDonald, P.E.2    Gaisano, H.Y.3    Wheeler, M.B.4
  • 82
    • 2642705036 scopus 로고    scopus 로고
    • A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events
    • Fraser ID, Tavalin SJ, Lester LB et al. A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. EMBO J 1998; 17: 2261-2272.
    • (1998) EMBO J , vol.17 , pp. 2261-2272
    • Fraser, I.D.1    Tavalin, S.J.2    Lester, L.B.3
  • 83
    • 0031434473 scopus 로고    scopus 로고
    • Anchoring of protein kinase A facilitates hormone-mediated insulin secretion
    • Lester LB, Langeberg LK, Scott JD. Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc Natl Acad Sci U S A 1997; 94: 14942-14947.
    • (1997) Proc Natl Acad Sci U S A , vol.94 , pp. 14942-14947
    • Lester, L.B.1    Langeberg, L.K.2    Scott, J.D.3
  • 85
    • 0037232658 scopus 로고    scopus 로고
    • 2+ release in INS-1 pancreatic β cells
    • 2+ release in INS-1 pancreatic β cells. J Physiol 2003; 546: 175-189.
    • (2003) J Physiol , vol.546 , pp. 175-189
    • Kang, G.1    Holz, G.G.2
  • 86
    • 0033829562 scopus 로고    scopus 로고
    • 2+ and electrolyte mobilization following agonist application to the pancreatic β cell line HIT
    • 2+ and electrolyte mobilization following agonist application to the pancreatic β cell line HIT. Pflugers Arch 2000; 440: 828-834.
    • (2000) Pflugers Arch , vol.440 , pp. 828-834
    • Nakagaki, I.1    Sasaki, S.2    Hori, S.3    Kondo, H.4
  • 88
    • 0034490218 scopus 로고    scopus 로고
    • 3 receptor and its role in β cell function
    • 3 receptor and its role in β cell function. Cell Mol Life Sci 2000; 57: 1938-1949.
    • (2000) Cell Mol Life Sci , vol.57 , pp. 1938-1949
    • Hagar, R.E.1    Ehrlich, B.E.2
  • 92
    • 0030792753 scopus 로고    scopus 로고
    • Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells
    • Renström E, Eliasson L, Rorsman P. Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J Physiol 1997; 502(Pt 1): 105-118.
    • (1997) J Physiol , vol.502 , Issue.PART 1 , pp. 105-118
    • Renström, E.1    Eliasson, L.2    Rorsman, P.3
  • 93
    • 0037337832 scopus 로고    scopus 로고
    • SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells
    • Eliasson L, Ma X, Renström E et al. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 2003; 121: 181-197.
    • (2003) J Gen Physiol , vol.121 , pp. 181-197
    • Eliasson, L.1    Ma, X.2    Renström, E.3
  • 94
    • 0037103455 scopus 로고    scopus 로고
    • Synergistic effect of dimethyl sulfoxide on glucagon-like peptide 1 (GLP-1)-stimulated insulin secretion and gene transcription in INS-1 cells: characterization and implications
    • Kemp DM, Habener JF. Synergistic effect of dimethyl sulfoxide on glucagon-like peptide 1 (GLP-1)-stimulated insulin secretion and gene transcription in INS-1 cells: characterization and implications. Biochem Pharmacol 2002; 64: 689-697.
    • (2002) Biochem Pharmacol , vol.64 , pp. 689-697
    • Kemp, D.M.1    Habener, J.F.2
  • 95
    • 67649666737 scopus 로고    scopus 로고
    • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    • Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
    • (2009) Lancet , vol.374 , pp. 39-47
    • Buse, J.B.1    Rosenstock, J.2    Sesti, G.3
  • 96
    • 33847021177 scopus 로고    scopus 로고
    • Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1
    • de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007; 56: 438-443.
    • (2007) Diabetes , vol.56 , pp. 438-443
    • de Heer, J.1    Holst, J.J.2
  • 97
    • 67650490677 scopus 로고    scopus 로고
    • Exenatide exhibits dose-dependent effects on glycemic control over 12weeks in Japanese patients with suboptimally controlled type 2 diabetes
    • Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009; 56: 415-424.
    • (2009) Endocr J , vol.56 , pp. 415-424
    • Kadowaki, T.1    Namba, M.2    Yamamura, A.3    Sowa, H.4    Wolka, A.M.5    Brodows, R.G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.